News in gastroenterology, hepatology and digestive endoscopy

Česká verzia

Authors: Přemysl Falt ¹; Dana Uricová ²; Tomáš Fejfar ³; Štěpán Šembera ³; Ilja Tachecí ³
Authors place of work: II. interní klinika gastroenterologická a geriatrická, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci ¹; Klinické a výzkumné centrum pro střevní záněty, ISCARE, Farmakologický ústav, 1. LF UK, Praha ²; II. interní gastroenterologická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Karlovy v Hradci Králové ³
Published in the journal: Vnitř Lék 2023; 69(3): 198-206
Category: News in...
doi: https://doi.org/10.36290/vnl.2023.034

Summary

Gastroenterology, hepatology and digestive endoscopy are rapidly evolving disciplines with significant advances in the diagnostics and treatment in the entire gastrointestinal tract. The aim of our article was to summarize new perspectives on relevant situations in gastroenterology and hepatology like acute pancreatitis, functional dyspepsia, rational indication of proton pump inhibitors, inflammatory bowel diseases (IBD), cholestatic liver diseases, alcohol induced hepatitis, non-alcoholic fatty live disease (NAFLD) and patophysiology of bilirubin and bile acids. Digestive endoscopy represents an interventional part of gastroenterology and key recent topics are mentioned like pancreatic cancer screening, arteficial intelligence, resection of low-risk neoplastic lesions, enteroscopy techniques, cholangio- and pancreatiscopy and extraluminal expansion of endoscopy techniques by means of endoscopic submucosal and transmural dissection, endoscopic myotomy and lumen apposing stents.

Keywords:

digestive endoscopy – gastroenterology – hepatology

Zdroje

1. de‑Madaria E, Buxbaum JL, Maisonneuve P, et al. Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis. N Engl J Med. 2022;387(11):989-1000.

2. Manak J. 2022. Těžká akutní pankreatitida. Klinické doporučené postupy [online]. Agentura pro zdravotnický výzkum České republiky (AZV ČR) [Cit. 6. 4. 2023]. Available from: https://kdp.uzis.cz/res/guideline/37-tezka‑akutni‑pankreatitida‑final. pdf

3. Rej A, Sanders DS, Shaw CC, et al. Efficacy and Acceptability of Dietary Therapies in Non‑Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten‑Free Diet. Clin Gastroenterol Hepatol. 2022;20(12):2876-87 e15.

4. El‑Salhy M, Winkel R, Casen C, et al. Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation. Gastroenterology. 2022;163(4):982-94 e14.

5. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De‑Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022;162(4):1334-42.

6. Grossberg LB, Papamichael K, Cheifetz AS. Review article: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(7):789-804.

7. Pippis EJ, Yacyshyn BR. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflamm Bowel, DiS. 2021;27(10):1674-83.

8. Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021;385(14):1280-91.

9. Sandborn WJ, Peyrin‑Biroulet L, Sharara AI, et al. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022;20(3):591-601 e8.

10. Feagan BG, Danese S, Loftus EV, Jr., et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2 b/3 double‑blind, randomised, placebo‑controlled trial. Lancet. 2021;397(10292):2372-84.

11. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double‑blind, randomised trials. Lancet. 2022;399(10341):2113-28.

12. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806.

13. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of cystic liver diseases. J Hepatol. 2022;77(4):1083-108.

14. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-24.

15. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502.

16. de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double‑Blind, Randomized, Placebo‑Controlled Trial. Gastroenterology. 2021;160(3):734-43 e6.

17. Weinberg EM, Dukewich M, Jakhete N, et al. Early Liver Transplantation for Severe Alcohol‑Associated Hepatitis and a History of Prior Liver Decompensation. Am J Gastroenterol. 2022;117(12):1990-8.

18. Murillo Perez CF, Fisher H, Hiu S, et al. Greater Transplant‑Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real‑World External Controls. Gastroenterology. 2022;163(6):1630-42 e3.

19. Zizalova K, Novakova B, Vecka M, et al. Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension. Liver Int. 2023;43(4):888-95.

20. Woronyczova J, Novakova M, Lenicek M, et al. Serum Bilirubin Concentrations and the Prevalence of Gilbert Syndrome in Elite Athletes. Sports Med Open. 2022;8(1):84.

21. Smid V, Dvorak K, Sedivy P, et al. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatol Commun. 2022;6(6):1336-49.

22. Hur C, Tramontano AC, Dowling EC, et al. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. Pancreas. 2016;45(7):1062-6.

23. Canto MI, Almario JA, Schulick RD, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long‑term Surveillance. Gastroenterology. 2018;155(3):740-51 e2.

24. Vaněk P, Zoundjiekpon V, Slodička P, et al. Screening karcinomu pankreatu: Nastal čas vykročit? Gastroenterol Hepatol. 2021;75(5):390-8.

25. Sharma A, Smyrk TC, Levy MJ, et al. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155(2):490-500 e2.

26. Lu Z, Zhang L, Yao L, et al. Assessment of the Role of Artificial Intelligence in the Association Between Time of Day and Colonoscopy Quality. JAMA Netw Open. 2023;6(1):e2253840.

27. Jain S, Seal A, Ojha A, Yazidi A, et al. A deep CNN model for anomaly detection and localization in wireless capsule endoscopy images. Comput Biol Med. 2021;137:104789.

28. Pimentel‑Nunes P, Libanio D, Bastiaansen BAJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2022. Endoscopy. 2022;54(6):591-622.

29. Falt P. Endoscopic treatment of early colorectal cancer. Vnitr Lek. 2022;68(6):355-62.

30. Falt P, Zapletalova J, Urban O. Endoscopic full‑thickness resection versus endoscopic submucosal dissection in the treatment of colonic neoplastic lesions